European Medicines Agency
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) BEROMUN
EPAR summary for the public
This document is a summary of the European Public Assessment Report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.
If you need more information about your medical condition or your treatment, read the Package Leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the Scientific Discussion (also part of the EPAR)._
What is Beromun?
Beromun is a powder and solvent that are made up into a solution for infusion. It contains the active substance tasonermin.
What is Beromun used for?
Beromun is used in patients with soft tissue sarcoma (a type of cancer) of the limb (arm or leg), together with melphalan (an anticancer medicine), using a technique called ‘isolated limb perfusion’ (ILP): both medicines are injected into the limb while the blood circulation in the limb is kept isolated (cut off) from the rest of the body. It can be used before surgery to reduce the size of a tumour, or instead of surgery when the tumour cannot be removed by surgery alone.
The medicine can only be obtained with a prescription.
How is Beromun used?
Beromun treatment should only be carried out in special centres by surgical teams who have experience in the treatment of this type of cancer and ILP. The centres must also have intensive care units readily available and facilities to continuously look out for leakage of the medicine into the rest of the body using radioactive tracers.
Before Beromun is given, the limb is first isolated: while the patient is under general anaesthetic, a tight band is placed around the top of the limb to isolate its blood supply and prevent the medicine reaching the rest of the body. The blood circulation in the limb is then replaced by the ‘perfusion’ of a special liquid and the limb is warmed to a temperature of between 38 and 39°C. Beromun is then injected into the perfusion solution at a dose of 3 mg for an arm and 4 mg for a leg, given over 90 minutes. Melphalan is given during the same operation over 60 minutes, beginning 30 minutes after the start of the Beromun perfusion, when the temperature should be increased to 39 to 40°C. The dose of melphalan depends on the size of the arm or leg. At the end of the 90-minute procedure, the medicines are flushed out of the limb using a suitable fluid. The remains of the tumour should be removed whenever this is possible, usually after several weeks.
Beromun is usually only used once, but a second perfusion can be considered six to eight weeks after the first. Beromun is not recommended for patients below 18 years of age, because of a lack of information on safety and effectiveness in this age group.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: email@example.com http://www.emea.europa.eu © European Medicines Agency, 2009. Reproduction is authorised provided the source is acknowledged.
The active substance in Beromun, tasonermin, is a copy of the human protein tumour necrosis factor alfa-1a (TNFa). The exact way that TNFa works against certain types of cancer is not fully understood, but it is thought that it can kill tumour cells directly, as well as destroy the blood vessels supplying tumours and stimulate the immune system to attack them. This leads to the tumour dying back and getting smaller, particularly when the medicine is combined with other cytotoxic (cellkilling) medicines and raised temperature.
The active substance in Beromun, tasonermin, is produced by a method known as ‘recombinant DNA technology’: it is made by bacteria that have received a gene (DNA), which makes them able to produce TNFa. The replacement TNFa acts in same way as the naturally produced protein.
How has Beromun been studied?
Beromun has been studied in four main studies involving a total of 188 patients, in which it was given in combination with melphalan. Sixty-two of the patients also received interferon-gamma (another anticancer medicine). A review of the studies by three independent experts found that only 145 of these patients were candidates for amputation or surgical removal of the tumour that would have resulted in significant loss of function (disability). Therefore, the main measure of effectiveness was based on the experts’ assessment of the outcome of these 145 patients, in comparison with the outcome that would be expected without using Beromun.
The independent reviewers agreed that 62% of the patients receiving Beromun and melphalan (90 out of 145) had a better outcome than predicted, since their limb was saved without surgery to remove the tumour or their tumour was removed without causing significant loss of function. There were too few patients also receiving interferon-gamma to determine whether this improved the patients’ outcome further.
What is the risk associated with Beromun?
Most patients taking Beromun experience fever, which is usually mild to moderate. Other side effects seen very commonly (in more than 1 patient in 10) are infection, cardiac arrhythmia (unstable heartbeat), nausea (feeling sick), vomiting, liver damage, fatigue (tiredness), chills, pain in the limb, nerve injury, skin reactions, oedema (swelling) and wound infection. Some side effects of Beromun are serious and could require a patient to spend time in an intensive care unit after treatment. For a more complete list of the side effects reported with Beromun, see the Package Leaflet.
Beromun should not be used in people who may be hypersensitive (allergic) to tasonermin or any of the other ingredients. It must not be used in patients with significant cardiovascular (heart and blood vessel) disease, severe lung disease, a recent or active stomach ulcer, severe ascites (fluid accumulation in the abdomen), blood disorders, kidney or liver disease, or hypercalcaemia (high blood calcium levels), or in women who are pregnant or breast-feeding. It must also not be used in patients who cannot receive vasopressors (medicines to increase the blood pressure), anticoagulants (medicines to prevent blood clotting) or medicines that can harm the heart. Beromun must not be used in patients who cannot receive melphalan or who cannot undergo ILP. See the Summary of Product Characteristics (also part of the EPAR) for the full list of restrictions.
Why has Beromun been approved?
The Committee for Medicinal Products for Human Use (CHMP) decided that Beromun’s benefits are greater than its risks as an adjunct to surgery for subsequent removal of the tumour so as to prevent or delay amputation, or in the palliative situation, for irresectable soft tissue sarcoma of the limbs, used in combination with melphalan via mild hyperthermic ILP. The Committee recommended that Beromun be given marketing authorisation.
Other information about Beromun:
The European Commission granted a marketing authorisation valid throughout the European Union for Beromun to Boehringer Ingelheim International GmbH on 13 April 1999. The marketing authorisation was renewed on 13 April 2004 and on 13 April 2009.
The full EPAR for Beromun can be found here.
This summary was last updated in 04-2009.